Going beyond the boundaries obvious in structural heart interventions

Mitral Regurgitation and Atrial Fibrillation

Fabián Nietlispach, MD PhD
Head Structural Interventions
Potential conflicts of interest

Speaker's name: Fabian Nietlispach

☑ I have the following potential conflicts of interest to report:

Receipt of grants / research support: Abbott

Receipt of honoraria or consultation fees: Abbott, Edwards Lifesciences
91 y/o htn, dyslip female in NYHA III-IV
AVA(LD) = 0.47 cm$^2$
LVOT D = 1.9 cm
LV V1 VTI = 11.1 cm
Ao V2 VTI = 64.5 cm
91 y/o charming lady

- lived independently at home (big house with garden)

- Co-morbidities
  - Previous SAVR (CE 19mm) and CABG
  - AF (CHADS-VASc 5)
  - CKD (GFR 21)

- Now admitted with acute heart failure NYHA III-IV d/t
  - Severe degenerative MR
  - Severe degenerative AS
What to do??

Options
– OMT
– Treat AS, leave MR
– Treat MR, leave AS
– Treat both

…and something is missing….

– LAA occlusion
  • HAS-BLED Score 3 → 5.8% annual risk for major bleeding
What to do??

• Options
  – OMT
  – Treat AS, leave MR
  – Treat MR, leave AS
  – Treat both (first AS, then MR, then LAAO)

...and....

– LAA occlusion
  • HAS-BLED Score 3 → 5.8% annual risk for major bleeding
Procedures
Debate

• Does it make sense at all?
  …in a 91 y/o → is age a criterion?

• Does LAAO make sense at all?
  …she didn’t have a major bleeding so far…

• Does it make sense in 1 procedure?
  …is it safer?
  …is patient comfort a criterion?
Follow-up

- Developed spontaneous eye bleeding on day 2
- Recovered and discharged after 6 days

Last follow up:
- 4. April 2017:
  - Lives independently at home
  - NYHA I-II
  - No bleeding events
  - Meds: Aspirin 100mg, Pravastatin 40mg
Kuwata, Nietlispach et al. EuroIntervention in press
“One-Stop Shop”

Safety of Combining Transcatheter Aortic Valve Replacement and Left Atrial Appendage Occlusion

Adrian Attinger-Toller, MD, Francesco Maisano, MD, Oliver Senn, MD, Maurizio Taramasso, MD, Samira Shakir, MD, Mathias Possner, MD, Steffen Gloekler, MD, Stephan Windecker, MD, Stefan Stortecky, MD, Thomas F. Lüscher, MD, Bernhard Meier, MD, Fabian Nellis, PhD
Comparison of Left Atrial Appendage Occlusion vs Standard Medical Therapy in Patients in AF Undergoing TAVI (TAVI/LAAO)

This study is currently recruiting participants.

See Contacts and Locations

Verified March 2017 by University of Zurich

Sponsor:
University of Zurich

Collaborator:
St. Jude Medical

Information provided by (Responsible Party):
University of Zurich

Locations

Switzerland

University Hospital Zurich  Recruiting
Zurich, ZH, Switzerland, 8001
Contact: Fabian Nietlispach, MD PhD
Contact: Ulrike Staenger, RN

Sponsors and Collaborators

University of Zurich
St. Jude Medical

Investigators

Principal Investigator: Fabian Nietlispach, MD PhD  University of Zurich

More Information

ClinicalTrials.gov Identifier: NCT03088098
First received: November 22, 2016
Last updated: March 22, 2017
Last verified: March 2017
History of Changes

Responsible Party: University of Zurich
ClinicalTrials.gov Identifier: NCT03088098  History of Changes
Other Study ID Numbers: 2015-0459
Study First Received: November 22, 2016
Last Updated: March 22, 2017
Thank you